A New Approach.  A Better Approach.
People Deserve Better Medicine
Not Just a Longer Life, a Better Life.

A New Approach.  A Better Approach.
People Deserve Better Medicine
Not Just a Longer Life, a Better Life.
Positive topline data from pivotal Phase III ADVOCATE trial demonstrates avacopan’s superiority over standard of care in ANCA-associated vasculitis
Learn about LUMINA, a clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome.
Learn about ACCOLADE, a clinical research study for people with C3 glomerulopathy.
NOW ENROLLING:
.A Phase 3 clinical trial to evaluate the safety and efficacy of avacopan in patients with ANCA-vasculitis »
Clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome – Now Enrolling.
RECENT NEWS:
ChemoCentryx to Present at Three Upcoming Investor Conferences »